Inovalon (INOV) Reports In-Line Q4 EPS

Inovalon (NASDAQ: INOV) reported Q4 EPS of $0.13, in-line with the analyst estimate of $0.13. Revenue for the quarter came in at $120.6 million versus the consensus estimate of $125.4 million.

GUIDANCE:

Inovalon sees FY2016 EPS of $0.57-$0.60, versus the consensus of $0.63. Inovalon sees FY2016 revenue of $510-520 million, versus the consensus of $525.8 million.

"We are pleased with the strong operational execution achieved in the fourth quarter which drove record results for the quarter and full year of 2015. The Company recorded its highest level of fourth quarter and annual revenue and Adjusted EBITDA in its history while, simultaneously, integrating the Avalere acquisition, launching new products such as QSI®-XL and Data Diagnostics™ into the marketplace, and substantially expanding our addressable market," said Keith Dunleavy, M.D., Inovalon's chief executive officer and chairman of the board.

He continued, "We enter 2016 with a strong foundation, significant interest in our expanding platform capabilities, and a clear vision of multiple contributing paths of growth. While components of the marketplace such as the ACA and related Co-Ops have resulted in certain headwinds to our previously expected growth in such areas, the many components of positive execution and strong market interest in our capabilities result in our continued confidence in our ability to drive growth in 2016 and the coming years, remaining on track for our five year goal of balanced growth and innovation, achieving revenues of more than $1 billion with EBITDA margins of 40% by 2020."

For earnings history and earnings-related data on Inovalon (INOV) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c